Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Head and neck cancer

4197 - A phase 1b/2 study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results


22 Oct 2018


Proffered paper session - Head and neck cancer


Clinical Research;  Immunotherapy

Tumour Site

Head and Neck Cancers


Ezra Cohen


Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287


E.E..W. Cohen1, K.J. Harrington2, D.S. Hong3, R. Mesia4, I. Brana5, P. Perez Segura6, T. Wise-Draper7, M.L. Scott8, P.D. Mitchell9, G.M. Mugundu10, P. McCoon8, C.E. Cook8, M. Mehta8, U. Keilholz11

Author affiliations

  • 1 San Diego Moores Cancer Center, University of California, 92093 - La Jolla/US
  • 2 Chester Beatty Laboratories, Institute of Cancer Research ICR, SW3 6JB - London/GB
  • 3 Department Of Investigational Cancer Therapeutics, MD Anderson Cancer Center, 77030 - Houston/US
  • 4 Servicio De Oncologia Medica, ICO L’Hospitalet, Barcelona/ES
  • 5 Department Of Medical Oncology, Vall D’Hebron Institute of Oncology, Barcelona/ES
  • 6 El Instituto De Investigación Sanitaria Del Hospital Clínico San Carlos, Hospital Clinico San Carlos, Madrid/ES
  • 7 Division Of Hematology-oncology, University of Cincinnati Cancer Institute, Cincinnati/US
  • 8 Oncology Translational Medicine Unit, Imed Biotech Unit, AstraZeneca Pharmaceuticals, Waltham/US
  • 9 Biometrics, Imed Biotech Unit, AstraZeneca Pharmaceuticals, Waltham/US
  • 10 Quantitative Clinical Pharmacology, Early Clinical Development,imed Biotech Unit, AstraZeneca Pharmaceuticals, Waltham/US
  • 11 Oncology, Charite Comprehensive Cancer Center, 10117 - Berlin/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4197


D activity may be enhanced by overcoming intratumoral immune suppression. DAN, an antisense oligonucleotide STAT3 inhibitor, and CX2i, a CXCR2 inhibitor, are being studied with D in patients (pts) with PD-L1 treatment naive/pretreated RM-HNSCC. Earlier data from this study suggested enhanced antitumor activity with DAN + D in these pts.1


Results from the dose escalation in solid tumor pts are as previously reported. The dose expansion evaluated objective response rate (ORR), duration of response (DOR), and correlative biomarkers in pts treated with second-line (2L) DAN 3 mg/kg QW + D 20 mg/kg or CX2i 40 mg BID + D 20 mg/kg in PD-L1 naive/pretreated pts, and with DAN or CX2i as monotherapies in PD-L1 naive pts. A new arm was added for first-line (1L) PD-L1 naive pts. We present biomarker, DOR and updated ORR data for DAN + D and CX2i + D in 2L PD-L1 naive pts.


At data cutoff (DCO) (21 Feb 2018) ORR for 2L PD-L1 naive pts receiving DAN + D was 26% (10/38; 95% CI 13.4%–43.1%) including 4 complete responses (CRs) and 6 partial responses (PRs) (7/10 pts in response are still ongoing at DCO); median DOR was not reached (NR) (range 5–70+ weeks). Responses were observed with DAN + D regardless of HPV status or PD-L1 expression. DAN + D’s safety profile was consistent with previous reports; adverse events (AEs) including transaminase elevations and thrombocytopenia were manageable and reversible. Comparison of pre- and on-treatment biopsies showed drug uptake in immune cells and fibroblasts, reductions in a suppressive cell gene expression signature (GES), and increases in an IFNy GES. Additional biomarker data, pharmacokinetic data, and emerging data for DAN + D in 1L PD-L1 naive pts will be presented. By contrast, in PD-L1 naive pts treated with CX2i + D the ORR was 10% (2/20; 1 CR, 1 PR), the median DOR was NR (range 6.7–38.4+ weeks), and causally related AEs occurred in 76% of pts.


These results suggest enhanced activity of DAN + D compared to CX2i + D or PD-L1 monotherapy in PD-L1 naive pts with RM-HNSCC and warrant further investigation. 1Cohen E, et al. Ann Oncol. 2017;28 (suppl 5):1135O.

Clinical trial identification


Legal entity responsible for the study




Editorial Acknowledgement

Medical writing assistance was provided by Ann Yeung, CMPP, PhD, of Scientific Pathways, Inc.


E.E.W. Cohen: Consultancy: Eisai, Pfizer, Merck, AstraZeneca, Bristol-Myers Squibb. K.J. Harrington: Consultancy, honoraria, speakers bureau, scientific advisory board memberships: Amgen, AstraZeneca, Bristol-Myers Squibb, Merck, MSD, Pfizer; Research funding: AstraZeneca, MSD. D.S. Hong: Consultancy: Baxter, Bayer, Guidepoint Global, Janssen; Research funding: Adapitmmune, AbbVie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi-Sanko, Eisai, Genentech, Genmab, Ignyta, Infinity, Kite Kyowa, Lilly, Loxo, Mirati, Merck, MedImmune, Molecular Template, Novartis, Pfizer, Takeda; Honoraria: Loxo, MiRNA; Ownership interest: Molecular Match (Advisor), Oncoresponse (Founder). R. Mesia: Speakers bureau: Merck, Bristol-Myers Squibb; Membership on any entity’s board of directors or advisory committees: Merck, Bristol-Myers Squibb, MSD, Roche, AstraZeneca. M.L. Scott, P.D. Mitchell, G.M. Mugundu, P. McCoon, C.E. Cook, M. Mehta: Employment: AstraZeneca. U. Keilholz: Consultancy: AstraZeneca, Bayer, Bristol-Myers Squibb, Glycotope, MSD, Merck Serono, Novartis, Pfizer; Research funding: AstraZeneca, Bayer, Glycotope, Pfizer; Honoraria: AstraZeneca, Bayer, Bristol-Myers Squibb, Glycotope, MSD, Merck Serono, Novartis, Pfizer; Speakers bureau: AstraZeneca, Bayer, Bristol-Myers Squibb, Glycotope, MSD, Merck Serono, Novartis, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.